Page 14 - HFA_Dateline_2019_Q1_Spring_SpecialEdition

VIII Recombinant Clotting Factor continued…

Manufacturer Product Type Half Life
Adults(>16 years)= 12.0 ± 4.2 hrs ;
Takeda Advate Recombinant Clotting Factor 5 to <12 yrs=11.2 ± 3.5 hrs; 2 to <5 yrs=9.5 ± 1.8 hrs;
1 month to <2 yrs=8.7 ± 1.4 hrs
(formerly Shire) ≥18 years= 14.69 ± 3.79 hrs; 12 to <18 years=
13.43 ± 4.05 hrs; 6 to <12 years= 12.4 ± 1.67 hrs;
Takeda Adynovate Recombinant Clotting Factor <6 years= 11.8 ± 2.43 hrs. Overall 1.3-1.5 half-life
extension compared to ADVATE
(formerly Shire) 14.6 hrs

Takeda Recombinate Recombinant Clotting Factor Half Life
12.2 hours (mean) in Hemophilia A
(formerly Shire) 17.5 hours (mean)

VIII Plasma-derived Clotting Factor 14.8 ± 3.0 hrs

Manufacturer Product Type Half Life
3.3-3.5 hours
CSL Behring Humate-P Plasma-derived Clotting Factor
~4 weeks
CSL Behring Monoclate-P Plasma-derived Clotting Factor

Grifols Alphanate Plasma-derived Clotting Factor

Kedrion Koate-DVI Plasma-derived Clotting Factor
BioPharma

Takeda Hemofil M NH Plasma-derived Clotting Factor

(formerly Shire)

VIII Other Products

Manufacturer Product Type
CSL Behring Nasal Spray
Stimate
Genentech (Desmopressin Therapeutic Bi-Specific Antibody
Nasal Spray)

HEMLIBRA

Pfizer Cyklokapron Antifibrinolytic Agent 2 hours (f)
(tranexamic
acid injection)

Sanofi-Aventis DDAVP Intravenous Injection-Factor catalyst/
(Desmopressin) factor booster/factor precipitator

Every effort has been made ensure the accuracy of the information in this list by using information directly from manufacturers and publicly-available information from websites, such
as the FDA. HFA does not encourage community members to use one product over another, and strongly urges you discuss your treatment options with qualified medical professionals.

14 Dateline Federation | Special Issue 2018-19